1. eEF2K/eEF2 Pathway Controls the Excitation/Inhibition Balance and Susceptibility to Epileptic Seizures.
- Author
-
Heise C, Taha E, Murru L, Ponzoni L, Cattaneo A, Guarnieri FC, Montani C, Mossa A, Vezzoli E, Ippolito G, Zapata J, Barrera I, Ryazanov AG, Cook J, Poe M, Stephen MR, Kopanitsa M, Benfante R, Rusconi F, Braida D, Francolini M, Proud CG, Valtorta F, Passafaro M, Sala M, Bachi A, Verpelli C, Rosenblum K, and Sala C
- Subjects
- Animals, Cells, Cultured, Cerebral Cortex drug effects, Cerebral Cortex enzymology, Cerebral Cortex pathology, Conditioning, Psychological physiology, Disease Models, Animal, Elongation Factor 2 Kinase antagonists & inhibitors, Elongation Factor 2 Kinase genetics, Epilepsy pathology, Fear physiology, Hippocampus drug effects, Hippocampus enzymology, Hippocampus pathology, Mice, Inbred C57BL, Mice, Knockout, Neural Inhibition drug effects, Neural Inhibition physiology, Neurons drug effects, Neurons pathology, Rats, Sprague-Dawley, Receptors, GABA-A metabolism, Synapsins genetics, Synapsins metabolism, Synaptic Transmission drug effects, gamma-Aminobutyric Acid metabolism, Elongation Factor 2 Kinase metabolism, Epilepsy enzymology, Neurons enzymology, Synaptic Transmission physiology
- Abstract
Alterations in the balance of inhibitory and excitatory synaptic transmission have been implicated in the pathogenesis of neurological disorders such as epilepsy. Eukaryotic elongation factor 2 kinase (eEF2K) is a highly regulated, ubiquitous kinase involved in the control of protein translation. Here, we show that eEF2K activity negatively regulates GABAergic synaptic transmission. Indeed, loss of eEF2K increases GABAergic synaptic transmission by upregulating the presynaptic protein Synapsin 2b and α5-containing GABAA receptors and thus interferes with the excitation/inhibition balance. This cellular phenotype is accompanied by an increased resistance to epilepsy and an impairment of only a specific hippocampal-dependent fear conditioning. From a clinical perspective, our results identify eEF2K as a potential novel target for antiepileptic drugs, since pharmacological and genetic inhibition of eEF2K can revert the epileptic phenotype in a mouse model of human epilepsy., (© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF